Loss-of-function mutations in lysine methyltransferase 2 (KMT2C) are frequently observed in breast cancer and are significantly associated with enhanced tumour heterogeneity, aggressive clinical behaviour, and poor prognosis. This evidence concerns the gene KMT2C and breast cancer.